Meeting Report

Updates in the Management of Renal Cell Carcinoma

Kirollos S. Hanna,(1) PharmD, BCPS, BCOP, and Zita D. Lim,(2) PA-C

From (1)M Health Fairview and Mayo Clinic College of Medicine, Maple Grove, Minnesota; (2)The University of Texas MD Anderson Cancer Center, Houston, Texas

Presenters’ disclosures of conflicts of interest are found at the end of this article.


J Adv Pract Oncol 2022;13(3):315–319 | https://doi.org/10.6004/jadpro.2022.13.3.27 | © 2022 Harborside™


  

ABSTRACT

At JADPRO Live Virtual 2021, advanced practitioner experts reviewed clinical updates in the treatment of renal cell carcinoma, key patient counseling and monitoring considerations, and best practices to manage adverse events associated with therapies for renal cell carcinoma. 




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.